2022 |
In October 2022, Biocon Foundation, the CSR arm of the Bengaluru-headquartered Biocon Limited, was awarded the ‘Mahatma Award 2022 For Excellence in Social Good’.
In May 2022, Biocon Biologics and Viatris Inc launched a biosimilar product Abevmy (bBevacizumab) in Canada for use in the treatment of cancer.
In February 2022, Biocon got USFDA approval for its Posaconazole Delayed-Release tablets.
|
2021 |
Biocon Biologics received RS. 555 crore (US$ 75 million) capital from ADQ, an Abu Dhabi based primary equity investment
To expand its generic formulations portfolio, Biocon launched Everolimus tablets in the US.
Biocon Biologics Limited (BBL) and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance to develop antibodies for infectious diseases like dengue, HIV, and others.
|
2020 |
Biocon Biologics received US$ 150 million capital injection from Goldman Sachs Semglee (insulin glargine injection) launched in the US
Tata Capital acquired minority stake in Biocon Biologics
True North makes a primary equity investment in Biocon Biologics
|
2019 |
Bicara Therapeutics incorporated to advance novel immuno-oncology assets Ogivri, biosimilar Trastuzumab commercialised in the United States
Biosimilars business consolidated under independent entity Biocon Biologics Fulphila and Ogivri, jointly developed by Biocon and Mylan, was granted marketing authorisation by the European Commission
|
2018 |
Biocon, Sandoz entered global partnership for the next-generation biosimilars
Biocon and Mylan’s biosimilar Insulin Glargine, Semglee, received European approval for commercialisation
Fulphila, jointly developed by Biocon and Mylan, approved and launched in the United States.
|
2017 |
Biocon launched its biosimilar Bevacizumab in India
Biocon’s first overseas facility in Malaysia started operations
Biocon and Mylan becomes received US Food and Drug Administration (FDA) approval for biosimilar, Trastuzumab
|
2016 |
Japan's health regulator approved the sale of its biosimilar, Insulin Glargine, in partnership with FUJIFILM Toyama Chemical
|
2015 |
Biocon’s new insulin devices facility inaugurated in Bangalore
Biocon’s research services subsidiary, Syngene, debuted on the Indian stock market
|
2010 |
Biocon and Pfizer entered into a strategic global agreement
|
2009 |
Syngene inaugurated a fully dedicated research and development facility for Bristol-Myers Squibb at Biocon Park
Biocon launched Insulin Glargine under the brand name Basalog
Biocon, Mylan entered into strategic global partnership to develop biosimilars
|
2008 |
Biocon acquired stake in AxiCorp GmbH, a German pharmaceutical company
|
2007 |
Biocon divested its legacy enzymes business to Novozymes for US$115million to increase focus on developing, manufacturing biopharmaceuticals
|
2006 |
India's largest multiproduct Biologics facility was inaugurated Biocon Park, India’s first private Biotechnology SEZ, was inaugurated
|
2004 |
Biocon IPO was launched
Pichia-based rh-Insulin was developed and commercialised in India
|
2002 |
Biocon Biopharmaceuticals was established as a JV with CIMAB, Cuba
|
2002 |
Biocon Biopharmaceuticals was established as a JV with CIMAB, Cuba
|
1998 |
Biocon become an independent entity
|
1995 |
Unilever acquired 50% stake in Biochemizyme and created Biocon Quest India Ltd (BQIL), with Biocon and Unilever holding 50% stake each in the entity
|
1994 |
Biocon established Syngene International Pvt. Ltd
|
1989 |
Unilever acquired Biocon’s Irish Parent
|
1984 |
Biocon established Syngene International Pvt. Ltd
|